Horrow JC, Li W, Blobner M, et al. - Among morbidly obese adults dosed by actual (ABW) or ideal body weight (IBW) in this randomized, double-blind trial, researchers assessed sugammadex-mediated recovery time from rocuronium- or vecuronium-induced moderate (M-) or deep (D-) neuromuscular block. Participants had BMI ≥ 40 kg/m ² . Researchers assessed time to train of four ratio ≥ 0.9 for ABW as well as IBW groups pooled across neuromuscular blocking agent (NMBA)/blocking depth, evaluated by log-rank test stratified for agent and depth. Findings revealed that faster reversal without re-curarization was provided by ABW-based sugammadex dosing, favoring ABW-based sugammadex dosing in the morbidly obese, regardless of the depth of neuromuscular block or NMBA employed.